Prostate News Archive
04-Nov-2006
Faulty Gene Doubles Risk of Prostate Cancer (HealthDay via Yahoo! News)
THURSDAY, Nov. 2 (HealthDay News) -- Men who are missing sections of the CHEK2 kinase gene -- which programs production of a chemical that alerts the body to DNA damage -- are nearly twice as likely to develop prostate cancer as other men, a new study finds. Faulty Gene Doubles Risk of Prostate Cancer (MedicineNet.com)
Title: Faulty Gene Doubles Risk of prostate Cancer Category: Health News Created: 11/3/2006 2:05:00 AM Last Editorial Review: 11/3/2006 2:05:08 AM AMBFF: Study Shows Ambrilia's PSP94 Immunoassay to Have Prognostic Value in Prostate Cancer Management (Nasdaq)
Ambrilia Biopharma Inc. (AMBFF) announced that the findings of an extensive study conducted in collaboration with Dr. Dharam Ramnani, Laboratory Director at the Virginia Urology Pathology Laboratory, Richmond, Virginia, with its PSP94 (prostate Secretory Protein of 94 amino acids) immunoassay for the diagnosis and prognosis of prostate cancer, were published in the October 15th issue of Clinical
Back to Prostate News Archive
